Board of Directors

Ehud Marom

Mr. Marom is a founder of Pharma Two B and serves on its board since it was incorporated. In addition, Mr. Marom is Chairman & CEO of Mapi Pharma and Stem Cell Medicine. He brings vast experience in management, operations, business and strategic planning in the pharmaceutical industry, where he held the positions over the years. Past positions include VP of Operations at Teva Pharmaceuticals’ API and Innovative divisions; COO of Peptor Ltd; CEO of Gamida Cell (NASDAQ: GMDA) a leader in hematopoietic (blood) stem cell therapeutics; President and CEO of Makhteshim Chemical Works Ltd., followed by position of SVP of Supply Chain at Makhteshim-Agan Group (ADAMA ChemChina). Mr. Marom holds B.Sc. with distinction in Chemical Engineering from the Technion – Israel Institute of Technology.

Itamar Borowitz

Dr. Itamar Borowitz is Managing Partner of Crossroad VC, the high-tech investment arm of the Generali Insurance Group in Israel and Chairman of the China Israel Innovation Center in Futain District, Shenzhen, China. Dr. Borowitz is the Chairman of Yissum, the Technology Transfer Company of The Hebrew University of Jerusalem. He is a member of the Advisory Board of GLL Real Estate Partners GmBH. In the years 1992-2001 Dr. Borowitz was the CEO of the Phoenix Insurance Group, the Israel’s second largest insurance company, and in the years 1998-2001 the Chairman of the Israeli Insurance Association. Dr. Borowitz is a member of the Board of Governors of the of Tel Aviv University and member of the Board of Governors of the Hebrew University in Jerusalem, where he also serves as  a member of the Funds Committee and of the Investment Committee. Dr. Borowitz holds a PhD in Physics, and an MBA and a B.A. in General History from Tel Aviv University

Tomer Berkovitz

Dr. Tomer Berkovitz is a Managing Director & CFO at aMoon and has more than a decade of US capital markets experience. Prior to joining aMoon, he was the CFO & COO of Alcobra (NASDAQ: ADHD), a development-stage biotech company, where he led two successful public equity offerings from leading US healthcare funds and led Alcobra’s merger with Arcturus Therapeutics (NASDAQ: ARCT), a San-Diego based mRNA company.
Prior to joining Alcobra, he was an Executive Director in J.P. Morgan’s Investment Banking Division in New York, Citigroup’s Investment Bank in New York, and served as an economist in the Financial Advisory Unit to the Chief of Staff of the Israel Defense Forces. Dr. Berkovitz holds a Ph.D. in Finance and Economics (with Distinction) from Columbia Business School and holds an M.Sc. in Finance and Accounting and a B.A. in Economics and Management from Tel-Aviv University.

David Jonas

Mr. Jonas is the founder, president and Chief Executive Officer of JVC Investment Partners LLC, a firm that provides private investment and strategic support in the healthcare space. Mr. Jonas founded PharMEDium Healthcare Corporation (industry’s leader and preeminent provider of hospital sterile compounding services for IV and Epidural therapies, a $10 billion market in the USA.)and was its Chairman and Chief Executive Officer. Prior to founding JVC Investment Partners and PharMEDium, Mr. Jonas held  a number of senior management  position with Baxter including its co-founder of  Renal Therapy Services Worldwide Inc. He serves and served on a number of privately held companies and not for profit organizations. Mr. Jonas holds B.Sc and MBA from Roosevelt University, Chicago Illinois.

Yuval Cabilly, Ph.D.

Dr. Yuval Cabilly is a Co-Founder and Managing Partner of Israel Biotech Fund. Dr. Cabilly has vast experience in identifying, funding and engaging in business development activities of Israeli biotech companies. Dr. Cabilly received his PhD in molecular cell biology from Tel Aviv University, where he focused his research on a neurodegenerative disease, and several of his articles have been published in well-known scientific journals.

David Kronfeld

Mr. Kronfeld is the Chairman of JK&B Capital, L.L.C., a venture capital firm, which he founded in 1995. Prior thereto he served as a General Partner at Boston Capital Ventures, the Vice President of Acquisitions and Venture Investments at Ameritech, a Senior Manager at Booz Allen & Hamilton and a Systems Analyst at Electronic Data Systems.  Since February 2010, Mr. Kronfeld has been a director, and a member of the compensation committee, of Dynasil Corporation of America (NASDAQ-GM:DYSL). Mr.Kronfeld holds MS in Computer Science from Stevens Institute of Technology and MBA from Wharton Business School.

Alex Mogle

Alex Mogle is the VP Corporate Development of Mapi Pharma and has over 15 years of executive experience in the life science and chemical industries. From 2003 until 2012, Mr. Mogle served in several capacities, including company secretary, investor relations director and as the head of the supply chain of Makhteshim Agan Industries Ltd. (currently ADAMA), and was responsible for sales planning and inventory management which is valued at over $1 billion. Prior to Makhteshim Agan Industries Ltd., Mr. Mogle served as business development manager of the digital video division of Nice Systems Ltd., and as an economist in the Israeli Ministry of Finance. Mr. Mogle has a B.A., with honors, in economics and an MBA, majoring in finance and accounting, both from the Hebrew University of Jerusalem, Israel.

We at PharmaTwoB are
striving to make your
life better by developing
innovative, products
based on previously
approved drugs.